Drug Profile
Research programme: receptor protein tyrosine kinase antagonists - Juno Therapeutics
Latest Information Update: 09 Mar 2018
Price :
$50
*
At a glance
- Originator X-BODY BioSciences
- Developer Juno Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action Receptor protein-tyrosine kinase antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-small cell lung cancer; Solid tumours
Most Recent Events
- 06 Mar 2018 Juno Therapeutics has been acquired by Celgene Corporation
- 16 Jul 2016 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)